Gold Silver Reports – Cipla Says Eight Observations By U.S. FDA For Goa Unit Are Procedural — Cipla Ltd. received eight observations regarding manufacturing practices at its Goa plant that contributes a quarter of the drugmaker’s sales in the U.S.
The facility of India’s second-largest pharma company by market value was inspected from Jan. 22 -25, according to a Form 483 issued by the U.S. Food and Drug Administration.
Shares of Cipla declined 0.9 percent to Rs 555.60 apiece.
